Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death
Open accessThe DOI matches its Crossref record; 131 of the 135 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Named as the guardian of the genome, p53 is a tumor suppressor that regulates cell function, often through many different mechanisms such as DNA repair, apoptosis, cell cycle arrest, senescence, metabolism, and autophagy. One of the genes that p53 activates is MDM2, which forms a negative feedback loop since MDM2 induces the degradation of p53. When p53 activity is inhibited, damaged cells do not undergo cell cycle arrest or apoptosis. As 50% of human cancers inactivate p53 by mutation, current research focuses on reactivating p53 by developing drugs that target the p53-MDM2 interaction, which includes the binding of MDM2 and phosphorylation of p53. The objective of this article is to provide a short list and description of p53-MDM2 antagonists that may be excellent candidates for inducing cancer cell death. Relevant articles were searched for and identified using online databases such as PubMed and ScienceDirect. Increasing p53 levels, by targeting the p53-MDM2 interaction, can help p53 play its role as a tumor suppressor and induce cancer cell death. Researchers have identified different compounds that can act as inhibitors, either by directly binding to MDM2 or by modifying p53 with phosphorylation. The results associated with the drugs demonstrate the importance of targeting such interactions to inhibit cancer cell growth, which indicates that the use of the compounds may improve cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although a limitation is the differing subcutaneous tumor microenvironment, there is strong evidence that the cytotoxicity of MDM2 inhibitors is largely tumor cell autonomous (39, 40).”
From Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma (2025) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Panche, A. N., Diwan, A. D., & Chandra, S. R. (2016) · Journal of Nutritional Science · doi:10.1017/jns.2016.41 · Cited by 5,298
Chemistry and Biological Activities of Flavonoids: An Overview
Kumar, S., & Pandey, A. K. (2013) · The Scientific World Journal · doi:10.1155/2013/162750 · Cited by 4,980
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 4,252
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage
Banin, S., Moyal, L., Shieh, S.-Y., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., et al. (1998) · Science · doi:10.1126/science.281.5383.1674 · Cited by 1,797
Concepts in sumoylation: a decade on
Geiss-Friedlander, R., & Melchior, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2293 · Cited by 1,785
γH2AX: a sensitive molecular marker of DNA damage and repair
Mah, L.-J., El-Osta, A., & Karagiannis, T. C. (2010) · Leukemia · doi:10.1038/leu.2010.6 · Cited by 1,557
Cited by
Items 101–155 of 155
Modifying platelets at their birth: anti-thrombotic therapy without haemorrhage
Feely, C., Kaushal, N., D’Avino, P. P., & Martin, J. F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1343896 · Cited by 1
Gui, K., Li, X., Song, J., Li, A., Fan, J., & Huang, L. (2025) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.70384 · Cited by 1
Exemestane induces liver toxicity in zebrafish larvae by upregulating the p53 signaling pathway
Li, W., Zhou, X., Chen, W., Hu, W., Wang, Z., Xiao, Z., Yuan, W., Lian, J., Xiao, J., Cao, Z., et al. (2025) · Fish Physiology and Biochemistry · doi:10.1007/s10695-025-01588-7 · Cited by 1
Ubiquitin E3 Ligases and p53 in Doxorubicin-Induced Cardiotoxicity
Tachibana, S., Otaki, Y., Goto, J., Watanabe, T., & Watanabe, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110252 · Cited by 2
Deng, W., Gao, S., Yan, L., Su, Q., & Chen, S. (2026) · Pharmaceuticals · doi:10.3390/ph19030476 · Cited by 1
lncRNA-803 Suppresses Apoptosis in DF-1 Cells via the miR-6555-3p/MDM4/p53 Axis
Han, S., Yang, J., Qiu, Y., Zhao, S., Jiang, Y., Han, L., & Han, L. (2026) · Genes · doi:10.3390/genes17040440 · Cited by 1
Rakib, M. A., Hossain, B., Tanni, J. A., Hossain, M. S., Sium, M. S. H., Tushar, S., Anjum, M. T., Rahman, S., Zaman, M. S., Islam, M. B., et al. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146299 · Cited by 1
Breaking the bonds: targeting protein dimerization for prostate cancer therapy
Singh, N., & Heemers, H. V. (2026) · Endocrinology · doi:10.1210/endocr/bqag056 · Cited by 1
ATRX Knockdown Enhances Irradiation‐Induced Mitotic Catastrophe in p53‐Deficient Cancer Cells
Qin, L., Liu, R., Xu, W., Yu, L., Li, W., Lian, X., & Wang, Z. (2026) · Cell Biology International · doi:10.1002/cbin.70161 · Cited by 1
The role of e3 ubiquitin ligases and deubiquitinating enzymes in hepatocellular carcinoma
Wang, L., Zhang, H., Hu, Y., Li, X., Liu, J., & Liang, Y. (2026) · Cell Biology and Toxicology · doi:10.1007/s10565-026-10192-1 · Cited by 1
Liu, J., Huo, M., Wu, S., Wang, Z., Peng, S., & Fu, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08320-w · Cited by 1
Zhang, R., Wang, F., Li, J., Li, H., Zhang, N., Chen, H., Liu, X., Li, X., Wei, Z., Zhong, F., et al. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112665 · Cited by 1
Yang, F., Zhang, X., Ji, J., Li, S., 房祥杰, Yang, L., & Guo, X. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70613 · Cited by 1
Aswathy, R., Suganya, K., Varghese, C. A., & Sumathi, S. (2024) · The Journal of Obstetrics and Gynecology of India · doi:10.1007/s13224-024-01954-0 · Cited by 2
Effect of deubiquitinases in head and neck squamous cell carcinoma (Review)
Wang, J., Wu, L., Tian, Z., & Chen, J. (2025) · Oncology Letters · doi:10.3892/ol.2025.15053 · Cited by 2
Li, Y., Wang, Y., Shen, R., Liu, W., & Zhu, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1494007 · Cited by 2
Recent Advancements on the Anti-Tumor Small Molecule Inhibitors Targeting the p53-MDM2 Interaction
丁, 涵. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381881 · Cited by 2
Role of Tumor Suppressor Genes in Carcinogenesis: A Narrative Review
Universidad de Guanajuato, G., Figueroa, B. A. C., Guzmán, B. I. L., (BUAP), B. U. A. D. P., Rodríguez, R. R., Universidad michoacana de San Nicolás de Hidalgo, M., Gutierrez, F. D. J. M. D. C., Universidad de Guadalajara, G., García, J. I. P., Universidad Del Valle de México, G., et al. (2023) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v3-i11-32 · Cited by 1
R400: A novel gene signature for dose prediction in radiation exposure studies in humans
Peter, F. S., Vadrev, S. M., & Soufan, O. (2022) · Frontiers in Systems Biology · doi:10.3389/fsysb.2022.1022486
Liu, J., Tang, S., Yan, J., & Ye, T. (2023) · Molecules · doi:10.3390/molecules28020780
Hdm2 disrupts HdmX-mediated nuclear export of p53 by sequestering it in nucleus
Ni, Y., Chen, H., Cheng, X., Sun, B., Wu, Z., Zhan, Q., & Zhuang, Z. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114185
Mao, M., Zhuang, Y., & Yu, H. (2024) · Computer Methods in Biomechanics & Biomedical Engineering · doi:10.1080/10255842.2024.2433113 · Cited by 1
Perkasa, D. P., Kurnia, I., Fakih, T. M., Kisnanto, T., Ramadhani, D., Surniyantoro, H. N. E., Tuasikal, B. J., Forentin, . M., & Syaifudin, M. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e139559
Fu, X., Zhao, J., Liu, Q., Jia, J., & Wang, M. (2025) · International Journal of Radiation Research · doi:10.61186/ijrr.23.2.34
Loss of tumour suppressor p53 rewires enhancer landscape and governs oncogenic progressionPreprint
Rani, H., Notani, D., & Mahadevan, V. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.28.667341
The GNL3L ‐ MDM2 Interaction Drives Esophageal Squamous Cell Carcinoma Progression
Yang, A., Song, H., & Cheng, Y. (2025) · Cancer Medicine · doi:10.1002/cam4.71146
Molecular Characteristics, Circularization Mechanism, and Potential Functions of circRNA-0172
Wang, H., Li, W., Yang, T., Bai, H., Qiu, L., & Chang, G. (2025) · Genes · doi:10.3390/genes16111282
Fu, J., Liu, S., Zhao, R., Liu, W., Hayashi, T., Mizuno, K., Hattori, S., Fujisaki, H., & Ikejima, T. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117602
Protein arginine methylation and ubiquitination: A prominent crosstalk and its functions in cancer
Zhou, J., Zhang, A., Zhu, J., Tang, F., Yuan, Z., Ma, W., Wang, Q., Lü, J., Li, S., & Li, Z. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101997 · Cited by 1
Liu, Z. Q., Xia, G., Liang, X., Li, B., & Deng, J. (2024) · Figshare · doi:10.6084/m9.figshare.26752966
Liu, Z. Q., Xia, G., Liang, X., Li, B., & Deng, J. (2024) · Figshare · doi:10.6084/m9.figshare.26752963
Giercuszkiewicz-Haśnik, K., Pawicka, P., Jeleń, M., MORAK-MŁODAWSKA, B. I., & Skonieczna, M. (2026) · ACS Omega · doi:10.1021/acsomega.5c04145 · Cited by 1
Gozzellino, L., Costa, A. F., Nannini, M., Nigro, M. C., Pizzi, C., Angeli, F., Bergamaschi, L., Baldovini, C., Corti, B., Sciascio, L. D., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1723978
Ning, Y., Liang, Y., & Huang, Y. (2026) · Cytotechnology · doi:10.1007/s10616-026-00935-7
Kamel, E. M., Khadrawy, S. M., Ali, M. A. M., Ahmed, N. A., Yassin, N. Y. S., Alkhedhairi, S., Alkhayl, F. F. A., & Lamsabhi, A. M. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117951
Zhang, Y., Xun, C., Shi, C., Wang, R., Gao, Y., Pan, D., Guo, Y., & Wei, L. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.04.019
Barbier, N. (2024) · theses.fr (ABES) · doi:10.70675/99c2b3c5z36bdz42fdz9878z99a368eb72e3
Zhu, Q., Gong, X., Zhang, S., Zhang, J., & Yan, H.-T. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-02970-x
Decoding Breast Cancer Mutational Signatures
Porwal, O., Upreti, K., Kshirsagar, P. R., Panwar, S. A., Sharma, A., Radhakrishnan, G. V., & Jain, R. (2026) · International Journal of Prognostics and Health Management · doi:10.36001/ijphm.2026.v17i1.4714
Self-citationHan, C., Fang, Q., Zhang, B., Yuan, Y., Xu, C., Yang, J., Wang, Y., Gao, M., Xiong, H., & 徐如祥 (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1815682
Cui, A., Nie, H., Sun, Z., Li, Z., Guo, J., Fan, S., Wang, X., & Xia, Y. (2026) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-169859
Liu, Y., Huang, Y., Chen, A., Han, L., Bian, L., Xu, X., & Li, Y. (2026) · Experimental Eye Research · doi:10.1016/j.exer.2026.111072
Cao, Y., Wei, J., Chen, Q., Wang, H. J., Mu, J., Lu, S., Yuan, M., El‐Magd, M. A., Xu, B., Wang, R., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03826-5
Li, W., He, L., Zhu, X., Zhou, H., Wang, X., Liu, Y., & Qiu, C. (2026) · Animal Diseases · doi:10.1186/s44149-026-00239-5
The role of p53-mediated signaling pathways in nicotine-induced cancer: a systematic review
Jiang, Q., Zhang, Z., Zhou, J., Zhou, T., & Wang, H. (2026) · Food and Chemical Toxicology · doi:10.1016/j.fct.2026.116215
Zhang, Z., Wang, J., Du, X., Liu, X., Liu, J., Li, H., Jiang, Y., He, K., Chen, X., & Han, Y. (2026) · Human Cell · doi:10.1007/s13577-026-01406-z
Chen, Y., Xie, N., Chen, Y., Ren, L., Zhu, W., Huang, Y., Shan, Y., & Xiang, P. (2026) · Food and Chemical Toxicology · doi:10.1016/j.fct.2026.116290
Synthetic Protein Mimetic Based Therapies for Neurodegeneration
Stillman, N. H. (2025) · Digital Commons - DU (University of Denver) · doi:10.56902/etdcrp.2025.171
Pilehvari, N., Fatemi, A., Lashkari, M., Valandani, H. M., Ashoub, M. H., & Khalilabadi, R. M. (2026) · Medical Oncology · doi:10.1007/s12032-026-03353-z
H ∞ and Structured Uncertainty Analysis of p53 Signalling: Robustness of Cellular Fate Decision
de la Cruz, N., Albornoz, W. E., & Rodríguez-González, J. (2026) · IEEE Control and System Graduate Research Colloquium (ICSGRC) · doi:10.1109/icsgrc69436.2026.11711025
de Jesus, A. B., Dao, H. B., Imani, A., Rodriguez, G. A., Shehata, M. S., Chandran, R. R., Fine, S. A., Lim, S. Y., To, M., Lofftus, S. Y., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1910235
Khalifa, N. K., & Hussein, M. K. (2026) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2026.100837
Cristazine inhibits HPV-positive cervical cancer cells via inducing caspase-dependent apoptosis
Jo, M. J., Kim, J. G., Yoo, S. H., Kim, C. H., Kim, J.-O., & Kim, G.-D. (2026) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/apjtb.apjtb_366_26
BindingDB (2025) · UC San Diego · doi:10.7270/q2571hks
BindingDB Entry 50023187: Recent advances in developing targeted protein degraders.
BindingDB (2026) · UC San Diego · doi:10.7270/q26t0sjf
Metadata
- Authors
- Koo, N., Sharma, A. K., & Narayan, S.
- Affiliations
- University of Florida (US)
- Penn State Cancer Institute (US)
- Corresponding author
- Narayan, Satya
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-04-30
- Volume
- 23
- Issue
- 9
- Pages
- 5005
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9103871
- OpenAlex
- W4225255854
- Cited by
- 153
- References
- 135
- Citations by year
- 2026: 32 · 2025: 46 · 2024: 43 · 2023: 19 · 2022: 13
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Department of Anatomy and Cell Biology, University of Florida
- Department of Pharmacology, Penn State University College of Medicine
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, MDM2, p53-MDM2 interaction, p53 reactivation, MDM2 inhibitors, p53 phosphorylation, tumor suppressor, cancer cell death, apoptosis, cell cycle arrest, cancer therapeutics
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Tumor Suppressor Protein p53, Cell Death, Apoptosis, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.